Ranbaxy Laboratories Ltd. can’t make
or distribute drug ingredients from a fourth plant in India for
the U.S. market, regulators ordered.
A U.S. Food and Drug Administration inspection of Ranbaxy’s
Toansa facility found that workers retested drug products to
produce acceptable findings after the items originally failed
analytical testing.
http://www.bloomberg.com/news/2014-01-23/ranbaxy-drugs-at-fourth-plant-banned-from-u-s-market.html
